Status:

TERMINATED

Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging

Lead Sponsor:

Medical University of Vienna

Conditions:

Primary Open Angle Glaucoma

Ocular Hypertension

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Glaucoma is among the leading causes for blindness in the western world. Elevated intraocular pressure (IOP) has been identified as the most important risk factor. However, some patients progress desp...

Eligibility Criteria

Inclusion

  • Healthy controls
  • Men and women aged over 18 years
  • Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
  • Normal ophthalmic findings
  • Patients with ocular hypertension
  • Men and women aged over 18 years
  • Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
  • Normal ophthalmic findings except presence of ocular hypertension (defined as untreated IOP ≥ 21 mmHg on at least three measurements in the medical history, no signs of glaucomatous damage in the optic disc or the glaucoma hemifield test)
  • Patients with primary open angle glaucoma
  • Men and women aged over 18 years
  • Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
  • Diagnosis of manifest primary open angle glaucoma (defined as pathological optic disc appearance, glaucoma hemifield test outside normal limits and untreated IOP \> 20 mmHg on at least three measurements in the medical history)
  • Mean Deviation in the visual field test ≥ 10dB
  • Patients with normal-tension glaucoma
  • Men and women aged over 18 years
  • Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
  • Diagnosis of normal-tension glaucoma (defined as pathological optic disc appearance, glaucoma hemifield test outside normal limits and untreated IOP ≤ 20 mmHg on at least three measurements in the medical history)
  • Mean Deviation in the visual field test ≥ 10dB

Exclusion

  • Symptoms of a clinically relevant illness in the 3 weeks before the first study day
  • Presence or history of a severe medical condition as judged by the clinical investigator
  • Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
  • Exfoliation glaucoma, pigmentary glaucoma, history of acute angle closure
  • Intraocular surgery within the last 6 months
  • Ocular inflammation or infection within the last 3 months
  • Pregnancy, planned pregnancy or lactating
  • Any metallic, electric, electronic or magnetic device or object not removable except dental fillings
  • Claustrophobia

Key Trial Info

Start Date :

November 1 2015

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2015

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT01864317

Start Date

November 1 2015

End Date

December 1 2015

Last Update

August 22 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Clinical Pharmacology

Vienna, Austria, 1090